|
|
|
Stem Cell Related Patent Number US6048724
| Title: | Method of producing clonal cell strains which express exogenous DNA encoding glucagon-like peptide 1 | | Inventors: | Selden, Richard F; Wellesley, MA, USA
Treco, Douglas; Arlington, MA, USA
Heartlein, Michael W.; Boxborough, MA, USA | | Summary: | This invention describes transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) that encodes erythropoietin or an insulinotropin (e.g., derivatives of glucagon-like peptide 1 (GLP-1)). Also disclosed are methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains that express erythropoietin or an insulinotropin, methods of gene therapy in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells. Also included are primary and secondary somatic cells, such as fibroblasts, keratinocytes, epithelial cells, endothelial cells, glial cells, neural cells, formed elements of the blood, muscle cells, other somatic cells that can be cultured and somatic cell precursors, which have been transfected with exogenous DNA encoding erythropoietin or an insulinotropin, which is stably integrated into their genomes or is expressed in the cells episomally. | | Abstract: | The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) that encodes erythropoietin or an insulinotropin (e.g., derivatives of glucagon-like peptide 1 (GLP-1)), methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains that express erythropoietin or an insulinotropin, methods of gene therapy in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells. The present invention includes primary and secondary somatic cells, such as fibroblasts, keratinocytes, epithelial cells, endothelial cells, glial cells, neural cells, formed elements of the blood, muscle cells, other somatic cells that can be cultured and somatic cell precursors, which have been transfected with exogenous DNA encoding erythropoietin or an insulinotropin, which is stably integrated into their genomes or is expressed in the cells episomally. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US6048724 | | Application Number: | US1995000446911 | | Date Filed: | 22/05/1995 | | Date Published: | 11/04/2000 | | Assignee: | Transkaryotic Therapies, Inc., Cambridge, MA, USA |
|
|
